DXCM Dexcom
FY2025 10-K
Dexcom (DXCM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
- • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
Management Discussion & Analysis
- • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
- • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
Risk Factors
- • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
- • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
Financial SummaryXBRL
Revenue
$4.7B
Net Income
$836M
Gross Margin
60.1%
Operating Margin
19.6%
Net Margin
17.9%
ROE
30.5%
Total Assets
$6.3B
EPS (Diluted)
$2.09
Operating Cash Flow
$1.4B
Source: XBRL data from Dexcom FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.